Vifor Pharma Stock

Vifor Pharma EBIT 2024

Vifor Pharma EBIT

543.66 M CHF

Ticker

VIFN.SW

ISIN

CH0364749348

WKN

A2DRZ4

In 2024, Vifor Pharma's EBIT was 543.66 M CHF, a 16.12% increase from the 468.18 M CHF EBIT recorded in the previous year.

The Vifor Pharma EBIT history

YEAREBIT (undefined CHF)
2026e948.4
2025e801.47
2024e543.66
2023e468.18
2022e408
2021351.8
2020260.3
2019325
2018227.4
2017134.3
2016236.4
2015451.84
2014370.19
2013390.4
2012345.9
2011326.9
2010320.9
2009263.9
2008263.4
2007154.3
2006111.6
2005101.8
200496.9
200391.3
200287.3

Vifor Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Vifor Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Vifor Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Vifor Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Vifor Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Vifor Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Vifor Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Vifor Pharma’s growth potential.

Vifor Pharma Revenue, EBIT and net profit per share

DateVifor Pharma RevenueVifor Pharma EBITVifor Pharma Net Income
2026e3 B undefined948.4 M undefined692.86 M undefined
2025e2.71 B undefined801.47 M undefined583.34 M undefined
2024e2.42 B undefined543.66 M undefined326.31 M undefined
2023e2.12 B undefined468.18 M undefined280.64 M undefined
2022e1.9 B undefined408 M undefined240.27 M undefined
20211.75 B undefined351.8 M undefined144.4 M undefined
20201.71 B undefined260.3 M undefined359.6 M undefined
20191.88 B undefined325 M undefined159.1 M undefined
20181.58 B undefined227.4 M undefined152.4 M undefined
20171.29 B undefined134.3 M undefined1.15 B undefined
20161.17 B undefined236.4 M undefined237.1 M undefined
20153.79 B undefined451.84 M undefined301.06 M undefined
20143.42 B undefined370.19 M undefined284.45 M undefined
20133.36 B undefined390.4 M undefined296.2 M undefined
20123.29 B undefined345.9 M undefined253.5 M undefined
20113.19 B undefined326.9 M undefined223.1 M undefined
20103.1 B undefined320.9 M undefined230.4 M undefined
20093.28 B undefined263.9 M undefined210.2 M undefined
20083.13 B undefined263.4 M undefined188.4 M undefined
20072.6 B undefined154.3 M undefined134.1 M undefined
20062.21 B undefined111.6 M undefined103.4 M undefined
20052.14 B undefined101.8 M undefined79.9 M undefined
20042.96 B undefined96.9 M undefined77.4 M undefined
20032.73 B undefined91.3 M undefined66.6 M undefined
20022.33 B undefined87.3 M undefined59 M undefined

Vifor Pharma stock margins

The Vifor Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vifor Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vifor Pharma.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Vifor Pharma's sales revenue. A higher gross margin percentage indicates that the Vifor Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Vifor Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Vifor Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Vifor Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Vifor Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Vifor Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Vifor Pharma Margin History

Vifor Pharma Gross marginVifor Pharma Profit marginVifor Pharma EBIT marginVifor Pharma Profit margin
2026e61.7 %31.63 %23.11 %
2025e61.7 %29.56 %21.51 %
2024e61.7 %22.43 %13.46 %
2023e61.7 %22.08 %13.24 %
2022e61.7 %21.48 %12.65 %
202161.7 %20.05 %8.23 %
202058.89 %15.26 %21.08 %
201959.43 %17.31 %8.48 %
201859.06 %14.35 %9.62 %
201759.91 %10.4 %88.81 %
201661.81 %20.26 %20.32 %
201521.16 %11.92 %7.94 %
201417.54 %10.84 %8.33 %
201317.31 %11.62 %8.82 %
201217.05 %10.5 %7.7 %
201116.41 %10.26 %7 %
201017.41 %10.34 %7.42 %
200923.9 %8.05 %6.42 %
200825.33 %8.42 %6.02 %
200716.91 %5.94 %5.16 %
200619.14 %5.04 %4.67 %
200518.43 %4.75 %3.73 %
200419.19 %3.28 %2.62 %
200319.08 %3.35 %2.44 %
200219.82 %3.75 %2.53 %

Vifor Pharma Aktienanalyse

What does Vifor Pharma do?

Vifor Pharma AG is a leading pharmaceutical company based in St. Gallen, Switzerland. The company has a long history and over 100 years of experience in the manufacturing of pharmaceutical products. It was founded in 1872 as Etablissements Gallois and has undergone various mergers and acquisitions. Today, it is part of the global Galenica Group and has branches in over 30 countries. Vifor Pharma AG focuses on the development and production of medications for the treatment of iron deficiency and kidney diseases. It diversifies its business across different market segments and geographic regions. The company's well-known products include iron preparations sold under different brands such as Ferinject, Injectafer, and Venofer, used for the treatment of iron deficiency anemia in both intravenous and tablet forms. another important business area for Vifor Pharma AG is nephrology, with a wide range of kidney and dialysis products available, including treatments for hyperphosphatemia and anemia in dialysis patients. To strengthen its innovation, the company has invested in partnerships, such as an exclusive license for the distribution of Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vifor Pharma AG has also invested in the digitalization and data-driven technologies, acquiring a stake in the Austrian company medisign GmbH in 2020 to expand its expertise in digital health and telemedicine. In terms of sustainability, the company aims to be carbon-neutral by 2025 and has implemented measures to reduce its CO2 footprint. With its long history, diverse portfolio of products and services, and investments in innovation and sustainability, Vifor Pharma AG is well-positioned for future success. Vifor Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Vifor Pharma's EBIT

Vifor Pharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Vifor Pharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Vifor Pharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Vifor Pharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Vifor Pharma stock

How much did Vifor Pharma achieve in EBIT for the current year?

In the current year, Vifor Pharma has achieved an EBIT of 543.66 M CHF.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Vifor Pharma.

How has the EBIT of Vifor Pharma developed in recent years?

The EBIT of Vifor Pharma has increased by 16.122% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Vifor Pharma?

The EBIT of Vifor Pharma is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Vifor Pharma pay?

Over the past 12 months, Vifor Pharma paid a dividend of 2 CHF . This corresponds to a dividend yield of about 1.2 %. For the coming 12 months, Vifor Pharma is expected to pay a dividend of 6.28 CHF.

What is the dividend yield of Vifor Pharma?

The current dividend yield of Vifor Pharma is 1.2 %.

When does Vifor Pharma pay dividends?

Vifor Pharma pays a quarterly dividend. This is distributed in the months of June, June, June, May.

How secure is the dividend of Vifor Pharma?

Vifor Pharma paid dividends every year for the past 24 years.

What is the dividend of Vifor Pharma?

For the upcoming 12 months, dividends amounting to 6.28 CHF are expected. This corresponds to a dividend yield of 3.78 %.

In which sector is Vifor Pharma located?

Vifor Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vifor Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vifor Pharma from 5/3/2022 amounting to 2 CHF, you needed to have the stock in your portfolio before the ex-date on 4/29/2022.

When did Vifor Pharma pay the last dividend?

The last dividend was paid out on 5/3/2022.

What was the dividend of Vifor Pharma in the year 2023?

In the year 2023, Vifor Pharma distributed 2 CHF as dividends.

In which currency does Vifor Pharma pay out the dividend?

The dividends of Vifor Pharma are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Vifor Pharma

Our stock analysis for Vifor Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vifor Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.